A Two-way Drug Interaction Study to Evaluate the Effect of BMS-955176 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2017
At a glance
- Drugs GSK 3532795 (Primary) ; Dolutegravir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 14 Jun 2016 Status changed from recruiting to completed.
- 20 Apr 2016 Status changed from not yet recruiting to recruiting.
- 28 Mar 2016 New trial record